Oxsynia Lp (Oxycodone Hydrochloride, Naloxone Hydrochloride Dihydrate)

Oxycodone Hydrochloride, the active ingredient in Oxsynia Lp, is an opioid analgesic presented as a solid oral dosage form for oral use. It treats moderate to severe pain in adult patients when other analgesics are insufficient. Naloxone Hydrochloride Dihydrate, the secondary ingredient, is included to mitigate opioid‑induced constipation and abuse potential.

GNH USA supplies Oxsynia Lp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oxycodone/Naloxone combination therapy is indicated for pain management within the opioid pathway, particularly for conditions requiring strong analgesia. - Chronic cancer pain: provides sustained relief while reducing opioid‑related side effects. - Severe postoperative pain: delivers potent analgesia after major surgery. - Chronic non‑cancer pain: offers long‑term control for patients with refractory pain where other treatments have failed.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel motility. - Dizziness: transient light‑headedness. - Somnolence: increased sleepiness. - Dry mouth: reduced salivation. - Pruritus: mild skin itching.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing requiring medical attention. - Severe hypotension: marked drop in blood pressure. - Hepatic impairment: liver function abnormalities. - Seizures: rare convulsive episodes. - Allergic reactions: rash, swelling, or anaphylaxis. - Dependence or withdrawal: signs of opioid use disorder.

When prescribing Oxsynia Lp, clinicians should evaluate patient history and monitor for specific risks. - Assess renal and hepatic function: adjust therapy if impairment is present. - Evaluate for respiratory disorders: avoid in severe COPD or sleep apnea. - Review concomitant CNS depressants: increased sedation risk. - Monitor for signs of abuse or dependence: educate patients on safe use. - Pregnancy and lactation: use only if benefits outweigh risks. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture and direct sunlight.

Oxycodone/Naloxone may interact with several medication classes, requiring clinical vigilance.

Major Interactions (Avoid): - Benzodiazepines: additive central nervous system depression. - CNS depressants: heightened risk of respiratory depression. - MAO inhibitors: potential for severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): increased oxycodone plasma levels. - CYP3A4 inducers (e.g., rifampicin): reduced analgesic effect. - Anticholinergics: may exacerbate constipation despite naloxone component.